Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 194

1.

The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.

Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A.

Oncologist. 2015 Jul;20(7):737-41. doi: 10.1634/theoncologist.2015-0065. Epub 2015 Jun 8.

PMID:
26054632
2.

Clinical next generation sequencing to identify actionable aberrations in a phase I program.

Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F.

Oncotarget. 2015 May 8. [Epub ahead of print]

3.

Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.

Said R, Kurzrock R, Naing A, Hong DS, Fu S, Piha-Paul SA, Wheler JJ, Janku F, Kee BK, Bidyasar S, Lim J, Wallace M, Tsimberidou AM.

Invest New Drugs. 2015 May 21. [Epub ahead of print]

PMID:
25990659
4.

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.

Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R.

Oncotarget. 2015 May 20;6(14):12809-21.

5.

Proceedings from the Turner Resource Network symposium: The crossroads of health care research and health care delivery.

Backeljauw PF, Bondy C, Chernausek SD, Cernich JT, Cole DA, Fasciano LP, Foodim J, Hawley S, Hong DS, Knickmeyer RC, Kruszka P, Lin AE, Lippe BM, Lorigan GA, Maslen CL, Mauras N, Page DC, Pemberton VL, Prakash SK, Quigley CA, Ranallo KC, Reiss AL, Sandberg DE, Scurlock C, Silberbach M.

Am J Med Genet A. 2015 Apr 29. doi: 10.1002/ajmg.a.37121. [Epub ahead of print]

PMID:
25920614
6.

A decision support framework for genomically informed investigational cancer therapy.

Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB.

J Natl Cancer Inst. 2015 Apr 11;107(7). pii: djv098. doi: 10.1093/jnci/djv098. Print 2015 Jul.

PMID:
25863335
7.

Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.

Hong DS, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R.

Invest New Drugs. 2015 Jun;33(3):621-31. doi: 10.1007/s10637-015-0226-6. Epub 2015 Mar 31.

PMID:
25822109
8.

Here and there: the art (and science) of psychotherapy.

Hong DS.

J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):157. doi: 10.1016/j.jaac.2014.12.013. No abstract available.

PMID:
25721178
9.

Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.

Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R.

Support Care Cancer. 2015 Feb 15. [Epub ahead of print]

PMID:
25680763
10.

Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.

Bilen MA, Fu S, Falchook GS, Ng CS, Wheler JJ, Abdelrahim M, Erguvan-Dogan B, Hong DS, Tsimberidou AM, Kurzrock R, Naing A.

Cancer Chemother Pharmacol. 2015 Apr;75(4):869-74. doi: 10.1007/s00280-015-2695-x. Epub 2015 Feb 10.

PMID:
25666183
11.

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer.

Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R.

Oncoscience. 2014 Aug 7;1(8):540-9. eCollection 2014.

12.

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors.

Tang C, Fontes Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS.

Oncoscience. 2013 Dec 11;1(1):5-13. eCollection 2014.

13.

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience.

Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, Kurzrock R, Subbiah V.

Oncoscience. 2014 Jul 27;1(7):522-30.

14.

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.

Hong DS, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS.

Oncotarget. 2014 Nov 30;5(22):11154-67.

15.

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Falchook GS, Wheler JJ, Naing A, Piha-Paul SA, Fu S, Tsimberidou AM, Hong DS, Janku F, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R.

Invest New Drugs. 2015 Feb;33(1):215-24. doi: 10.1007/s10637-014-0176-4. Epub 2014 Nov 4.

PMID:
25363205
16.

Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.

Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, Salgia R, Kurzrock R, Meric-Bernstam F, Hong DS.

Clin Cancer Res. 2014 Dec 15;20(24):6336-45. doi: 10.1158/1078-0432.CCR-14-1293. Epub 2014 Oct 17.

PMID:
25326232
17.

A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer.

Falchook GS, Moulder S, Naing A, Wheler JJ, Hong DS, Piha-Paul SA, Tsimberidou AM, Fu S, Zinner R, Janku F, Jiang Y, Huang M, Parkhurst KL, Kurzrock R.

Invest New Drugs. 2015 Feb;33(1):177-86. doi: 10.1007/s10637-014-0173-7. Epub 2014 Oct 18.

PMID:
25323060
18.

Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic.

Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, Meric-Berstam F, Hong DS.

Clin Cancer Res. 2014 Dec 1;20(23):5956-63. doi: 10.1158/1078-0432.CCR-14-1582. Epub 2014 Oct 14.

PMID:
25316815
19.

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.

Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM.

Oncotarget. 2014 Oct 15;5(19):8937-46.

20.

Here/in this issue and there/abstract thinking: Learning disorders and ADHD: are LDs getting the attention they deserve?

Hong DS.

J Am Acad Child Adolesc Psychiatry. 2014 Sep;53(9):933-4. doi: 10.1016/j.jaac.2014.06.006. No abstract available.

PMID:
25151413
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk